Physiologic disposition of nabilone, a cannabinol derivative, in man. 1977

A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer

Nabilone is a cannabinoid that is being evaluated in man as a potentially useful psychoactive drug. We found that nabilone was readily absorbed from the human gastrointestinal tract when administered orally as a coprecipitate with polyvinyl-pyrrolidone. The absorbed drug disappeared from plasma rather rapidly (half-life, approximately 2 hr), evidently due to extensive tissue distribution and rapid metabolism. The metabolites of nabilone persist in plasma for extended periods (half-life of total radioactivity exceeds 20 hr). Circulating metabolites include isomeric carbinols formed by reduction of the ketone in the 9-position of nabilone. Nabilone is eliminated in feces (about 65% of dose) and urine (20%). The excretory products in urine have not been identified, but metabolites that are labile to hydrolysis by beta-glucuronidase or sulfatase do not appear to be formed in significant amounts. A metabolite of nabilone in feces has been identified as a diol formed by reduction of the 9-keto group plus oxidation at the penultimate carbon of the dimethylheptyl side chain. The long duration of action of nabilone in the face of rapid and extensive metabolic elimination suggests that the pharmacologic effects, at least in part, may be exerted by one or more active metabolites.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D002245 Carbon Dioxide A colorless, odorless gas that can be formed by the body and is necessary for the respiration cycle of plants and animals. Carbonic Anhydride,Anhydride, Carbonic,Dioxide, Carbon
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002855 Chromatography, Thin Layer Chromatography on thin layers of adsorbents rather than in columns. The adsorbent can be alumina, silica gel, silicates, charcoals, or cellulose. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Thin-Layer,Thin Layer Chromatography,Chromatographies, Thin Layer,Chromatographies, Thin-Layer,Thin Layer Chromatographies,Thin-Layer Chromatographies,Thin-Layer Chromatography
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
December 1975, Clinical pharmacology and therapeutics,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
December 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
January 1963, Anesthesiology,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
April 1954, The Journal of pharmacology and experimental therapeutics,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
January 1965, Clinical pharmacology and therapeutics,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
July 1977, Cancer treatment reports,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
January 1973, Experientia,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
October 1977, Cancer treatment reports,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
January 1964, Clinical pharmacology and therapeutics,
A Rubin, and L Lemberger, and P Warrick, and R E Crabtree, and H Sullivan, and H Rowe, and B D Obermeyer
January 1975, Pharmacology,
Copied contents to your clipboard!